Billerica, MA 4/3/09—Bruker Advanced Supercon, a subsidiary of Bruker that provides low-temperature superconducting wire and high-temperature superconductor solutions, has acquired the research instruments portion of ACCEL Instruments GmbH from Varian Medical Systems for an undisclosed amount. Varian Medical retained ACCEL’s proton therapy business. As a result of the acquisition, Bruker has created two new subsidiaries: RI Research Instruments GmbH, which provides radio-frequency cavities and systems, linear accelerators, and special products for physics and energy research; and Bruker Advanced Supercon GmbH, which is focused on low- and high-temperature superconducting devices, circular accelerator vacuum systems, beamlines, X-ray optics and specialty superconducting magnets. RI Research Instruments is 45% owned by management, which includes Managing Directors Dr. Udo Klein and Dr. Michael Peiniger, the founders of ACCEL. “On an annualized basis, our newly acquired superconducting devices and energy research systems business is expected to generate revenue of greater than $25 million in year one, with near break-even results, and with significant growth potential in future years” stated Tom Rosa, senior vice president and CFO of Bruker Advanced Supercon. Dr. Burkhard Prause, CEO of Bruker Advanced Supercon commented: “Bruker plans to expand our new business in growth markets such as HTS superconducting fault current limiters for energy grid stabilization, crystal growth magnets for next-generation semiconductors, and superconducting devices and other core RI technologies for large-scale scientific and energy research facilities. We also expect to continue to supply OEM products to Varian in support of its proton therapy business for advanced cancer treatment.”